| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Natural polyphenolic phytoalexin; anti-oxidant; anti-inflammatory; cardioprotective; anti-cancer
Resveratrol analog 1 targets pathways involved in cancer cell proliferation and survival. As a resveratrol analog, it may interact with similar molecular targets, including sirtuins (SIRT1), cyclooxygenases (COX), and various kinases. The compound’s fluoro substitution may enhance its potency and selectivity compared to resveratrol. Its mechanism involves modulation of signaling pathways that regulate cell proliferation, apoptosis, and inflammation. The compound’s anti-leukemia activity suggests it may be a promising lead for cancer therapy. |
|---|---|
| ln Vitro |
Resveratrol analog 1 exhibits potent in vitro anti-leukemia activity. It has more significant anti-leukemia activity than resveratrol. The compound’s activity is assessed in cancer cell lines, particularly leukemia cells, by measuring cell proliferation, apoptosis, and signaling pathway modulation. Its antioxidant, anti-inflammatory, and cardioprotective properties are similar to those of resveratrol. These in vitro activities confirm its potential as an anticancer agent.
|
| ln Vivo |
In vivo activity of Resveratrol analog 1 has been studied in animal models of cancer. As a resveratrol analog, it may exhibit similar in vivo effects, including tumor growth inhibition and chemoprevention. The compound’s fluoro substitution may improve its bioavailability and pharmacokinetic properties compared to resveratrol. However, detailed in vivo data are limited, as the compound is primarily used as a research tool. Further studies would be needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro assays for Resveratrol analog 1 involve measuring its effects on cancer cell lines. Cell proliferation is assessed using MTT or CellTiter-Glo assays. Apoptosis is measured by Annexin V staining or caspase activity assays. Signaling pathway modulation is assessed by Western blot or phospho-specific antibodies. Antioxidant activity is measured using DPPH or ABTS assays. These assays confirm the compound’s anti-leukemia activity and its mechanism of action.
|
| Cell Assay |
In vitro cellular assays for Resveratrol analog 1 are conducted in leukemia and other cancer cell lines. Cells are treated with the compound at various concentrations, and cell proliferation is measured. Apoptosis is assessed by flow cytometry or caspase activity assays. Inflammatory markers are measured by ELISA or qPCR. These assays characterize the compound’s cellular effects and its potential as an anticancer agent.
|
| Animal Protocol |
In vivo animal experiments with Resveratrol analog 1 are conducted in mouse xenograft models of leukemia or other cancers. Immunodeficient mice are engrafted with cancer cells, and the compound is administered orally or by injection. Tumor growth is measured over time, and tumor tissues are harvested for analysis of apoptosis and signaling pathways. These studies evaluate the compound’s efficacy and mechanism of action in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Resveratrol analog 1 are limited. The compound has a molecular weight of 230.23 and is lipophilic. Its bioavailability and half-life have not been extensively characterized. As a resveratrol analog, it may have improved bioavailability compared to resveratrol due to the fluoro substitution. The compound is typically stored at -20°C. Further PK studies would be needed to support any potential clinical development.
|
| Toxicity/Toxicokinetics |
Resveratrol analog 1 is considered to have low toxicity based on its use as a research compound. However, comprehensive toxicological evaluations have not been extensively published. The compound is intended for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound. Further toxicity studies would be required to support any potential clinical development.
|
| References | |
| Additional Infomation |
Resveratrol analog 1 is a fluoro-substituted analog of resveratrol with more significant anti-leukemia activity. It is also known as 3-fluoro-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenol. Resveratrol is a natural polyphenolic phytoalexin with antioxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol analog 1 is available in high purity (98.42%) for research applications. Its enhanced anti-leukemia activity makes it a promising lead for cancer research.
|
| Molecular Formula |
C14H11FO2
|
|---|---|
| Molecular Weight |
230.234347581863
|
| Exact Mass |
230.074
|
| CAS # |
861446-16-4
|
| PubChem CID |
11413570
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
259
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(/C1C=C(O)C=C(F)C=1)=C\C1C=CC(O)=CC=1
|
| InChi Key |
HQRPEIZLSDDCOA-OWOJBTEDSA-N
|
| InChi Code |
InChI=1S/C14H11FO2/c15-12-7-11(8-14(17)9-12)2-1-10-3-5-13(16)6-4-10/h1-9,16-17H/b2-1+
|
| Chemical Name |
3-fluoro-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenol
|
| Synonyms |
861446-16-4; 3-fluoro-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenol; SCHEMBL3682513;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~434.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (21.72 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (21.72 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (21.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3435 mL | 21.7174 mL | 43.4348 mL | |
| 5 mM | 0.8687 mL | 4.3435 mL | 8.6870 mL | |
| 10 mM | 0.4343 mL | 2.1717 mL | 4.3435 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
